In the Digital Health and Startups category at the 2023 Consumer Electronics Show (CES), Eyenovia showcased its Microdose Array Print (MAP™) Technology, the first significant advancement in ocular drug delivery methods in over a century.

LAS VEGAS, January 31, 2023 (Newswire.com) - Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, showcased the Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas, Nevada, from Jan. 5-8. Eyenovia highlighted the technology and its human-centric approach to ocular drug delivery to over 115,000 attendees.

"CES 2023 is raising the bar for digital health innovation by bringing even more cutting-edge brands and technologies to the forefront," said Michael Rowe, CEO of Eyenovia. "We're honored to be among the impressive array of new innovations and brands taking center stage." 

The microdosing technology behind Optejet® prioritizes ease of use, appropriate dosing, and reducing wasted medication by administering one-fifth the volume of a solution compared to a traditional eyedropper. This method of drug delivery may reduce the risk of overdosing, which may lead to less adverse side effects and offers patients an easier, more precise way to dispense eye drop medications.

Eyenovia presented its latest human-centric innovations in the Digital Health and Startups category to an audience of over 4,700 media professionals and outlets. The 2023 Consumer Electronics Show brings together more than 3,200 exhibitors representing 173 countries, territories, and regions.

Eyenovia is creating an entire pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology. The Optejet® dispenser is the technology underlying Eyenovia's research and development targeting progressive myopia, presbyopia and mydriasis.

"CES 2023 is a testament to the rapid expansion of the digital health market, with an abundance of new brands and innovations being unveiled," concluded Rowe. "Our team is excited about the positive feedback and excitement, and we're looking forward to the opportunity to bring Optejet® to the consumer market if it receives regulatory approval."

Optejet® has not been approved, cleared, or licensed by the U.S. Food and Drug Administration for any use, and it is not commercially available in the United States. 

About Eyenovia, Inc.

Eyenovia, Inc. is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit www.eyenovia.com. 

Forward-Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws. Eyenovia does not undertake any obligation to update any forward-looking statements.

Contact Information:
Buse Kayar
[email protected]

Norbert Lowe
Vice President, Commercial Operations
[email protected]
Related Images


Original Source: Eyenovia Showcases Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas

Healthcare analytics firm secures Series D financing to invest in continued growth

JACKSONVILLE, Fla., January 31, 2023 (Newswire.com) - Clearsense®, a PaaS company that partners with healthcare organizations to increase data value, governance, and transparency, announced their successful $50M Series D capital raise led by HealthQuest Capital. The raise brought the healthcare-dedicated investment group to Clearsense with the shared goal of improving trust in enterprise data and expanding data-driven operations within healthcare organizations. HealthQuest was joined by existing investors Health Catalyst Capital and UPMC Enterprises.

"This investment into our organization further strengthens our mission to unlock the full potential of healthcare data by delivering solutions that empower data confidence and enable data-driven decision-making to achieve better outcomes," said Gene Scheurer, CEO of Clearsense. "We're elated to begin a relationship with HealthQuest, which shares the same vision: Transforming healthcare." 

Along with the raise, Clearsense welcomes new board member, Anthony Williams, partner at HealthQuest. Mr. Williams brings over 22 years of industry experience and serves as a Board Director for HealthQuest portfolio companies Perspectum, ENT Specialty Partners, and 83bar. 

Mr. Williams commented, "We seek to partner with transformative companies that meaningfully improve patient outcomes and economics across the healthcare ecosystem. Clearsense's platform accomplishes both of these objectives by enabling hospitals and health systems to utilize their data as a valuable asset. We're excited to partner with the company as it continues its impressive growth trajectory."

Clearsense's focus includes elevating health outcomes through data-based solutions and a commitment to promoting data literacy within healthcare. With 2023 poised to be a huge growth year for Clearsense, this new funding will allow Clearsense to further invest in infrastructure, technology, and people to drive the expansion of the 1Clearsense Data Management Platform.

Piper Sandler served as the sole placement agent and financial advisor in the transaction. 

About HealthQuest Capital

Based in the San Francisco Bay Area, HealthQuest Capital is a growth capital firm investing in commercial-stage companies that are optimizing value in healthcare by improving outcomes and reducing costs. With more than $1.6 billion in capital under management, the firm focuses on fostering innovation across the healthcare spectrum, including medical technologies, diagnostics/tools, digital health, and innovative services. The HealthQuest team combines decades of successful investing experience with deep domain expertise in all aspects of the healthcare industry. For more information, visit www.healthquestcapital.com.

About Clearsense

Committed to leading transformation in healthcare, Clearsense® creates a data journey, all the way from numbers to key insight. Cloud-based, AI-enabled, and HITRUST-certified, the platform of data applications ensure data governance, implementation, and analytics are rapidly mainstreamed while remaining scalable and secure. Driving faster outcomes in clinical, financial, and operational environments, Clearsense is powering the innovation of tomorrow—right now. Learn more at Clearsense.com.

# # #

Contact Information:
Kate-Madonna Hindes
Director of Marketing
[email protected]
612-501-7986


Original Source: Clearsense Announces Success of $50M Capital Raise

U.S. Towns and Cities Will Not Be Far Behind

WOBURN, Mass., January 31, 2023 (Newswire.com) - The Commune of Agen has reached an agreement with Fonroche Lighting to install 6,000 commercial solar street lights by 2026. This is the largest deployment of solar street light systems in Europe. The town worked with UGAP (Union of Public Purchasing Groups) to finalize the €11 million deal.

A Cost-Effective Decision

Upon completing a full street lighting survey, Fonroche identified 7,000 obsolete street light fixtures. Agen will replace them with 6,000 more efficient, solar powered lighting systems.

"Agen is the first region to switch so massively to photovoltaics," explains Jean Dionis du Séjour, president of Agen. "The investment is heavy, but the profitability is fast. We hope to save between 600,000 and 750,000 euros per year," adds the elected official.

The supplier of the new solar-powered street lighting, Fonroche Lighting, is based in Roquefort in the inner suburbs of Agen. The world leader in solar street lighting, the company employs around 200 people worldwide.

For the general manager of Fonroche Lighting, Laurent Lubrano, solar is a solution for the future. Many communities spend "40% to 60%" of their electricity bill on public lighting, against a backdrop of soaring prices.

"For communities today, the choice is: Either pay a lot of money or turn off and/or dim the lights. There is a third solution: invest in solar lighting. The sun is free," says the leader.

"The price of a commercial solar lighting system is higher than a traditional streetlight. But there is no additional cost: no electric bill, no trenching, no copper wiring, and no electric grid. With avoided installation costs, the return on investment is immediate. Plus, there is no maintenance for 10 years."

Lauren goes on to say that "There is no need for a lot of sun. For example, we have equipped a highway interchange in Calais with 120 streetlights which operate dusk to dawn every day of the year."

United States Municipalities Are Not Far Behind

Municipalities in the U.S. are experiencing many of the same pressures as Europe. They include rising energy prices, aging infrastructure, and poor lighting in underserved communities. Fonroche Lighting America has installed thousands of solar LED street lights across the USA.

When the City of Albuquerque launched its street light upgrade program, they found a place for solar too. Many areas that had either no street lighting or the neighborhood lighting had fallen into disrepair. They used the savings from a citywide conversion to energy efficient LED lighting to fund over 200 solar-powered LED street lights supplied by Fonroche Lighting America.

In the Midwest, Floyd County Indiana has embraced solar lighting too. 

"These environmentally-friendly lights are an excellent investment for Floyd County," noted Floyd County Com­missioner Shawn Carruthers. "As the cost of solar lighting has decreased and battery life has increased, this alter­native for illuminating our outdoor spaces has become more economically feasible. This newer technology ­represents good stewardship on behalf of Floyd County taxpayers. It provides immediate cost savings compared with regular parking lot lighting connected to the electrical grid."

Another municipality that found solar lighting to be an effective solution is Marana, Arizona. Project manager Mac Murray commented, "After carefully evaluating light levels, public works agreed the lighting levels were sufficient to ensure safety in the round-about."

These examples show that commercial solar lighting solutions are moving out of the specialty space and becoming the first choice for outdoor lighting.

Contact Information:
Ilze Greene
Marketing Director
[email protected]
9787601483
Related Images


Original Source: Agen & Fonroche Launch Largest Solar Lighting Project in EU

The conference provides continuing education and facilitates communication among interested sports medicine professionals.

BIG SKY, Mont., January 30, 2023 (Newswire.com) - ZetrOZ Systems will present new research on its sam® ultrasound device at the Big Sky Athletic Training Sports Medicine Conference in Big Sky, Montana, from Jan. 29 to Feb. 2. The program brings together athletic trainers and professionals across various disciplines of sports medicine in support of improving patient care.

Founder and CEO of ZetrOZ, Dr. George Lewis, will present on Combined Multicenter Randomized Placebo-Controlled Studies of Long Duration Continuous Ultrasound for Soft Tissue Pathology on Monday, Jan. 30, at 3:20 p.m. Mountain Standard Time.

The first evening will conclude with an NFL Playoff Welcome Reception co-hosted by ZetrOZ and DJO Orthopedics. Family and friends are invited to attend the reception, which will take place at 6 p.m. in the Jefferson Room at Big Sky Resort's Yellowstone Conference center.

"We are fortunate to have the opportunity to present at this year's conference," said Dr. Lewis. "It's an excellent opportunity for us to exchange ideas and share the benefits of sam® with a community of professionals dedicated to improving the health and performance of athletes."

The FDA has cleared ZetrOZ Systems' sam® as the only long-duration ultrasound device for prescription home use. The device uses multi-hour ultrasound to generate deep diathermy in tissue and is clinically proven to reduce chronic joint and back pain in multiple clinical trials. 

Meta-analyses demonstrate the device's unique ultrasound treatment algorithm is safe, effective, and a clinically valid treatment option for joint arthritis, upper neck, shoulder, and back pain, and the treatment of soft-tissue injuries. Additional studies report that daily sam® treatment reduced tendon pain by 90% in patients with chronic tendinopathy and arthritis pain by 40% in patients with moderate to severe knee osteoarthritis.

Registration is free of charge for sponsors, speakers, poster presenters, and students. Tickets are $150 for non-student attendees; a financial hardship option is available for $100. To register for the conference, visit https://bsatsmc.org/registration. 

To learn more, visit zetroz.com.

About ZetrOZ Systems

ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of +46 patents. The exclusive manufacturer and developer of the sam® product line is designed for the treatment of acute and chronic musculoskeletal conditions.

Contact Information:
Buse Kayar
[email protected]


Original Source: ZetrOZ Systems to Attend and Present at the Big Sky Athletic Training Sports Medicine Conference

Free Electronic Health Records for Physicians

SEATTLE, January 30, 2023 (Newswire.com) - Bellmedex, a leading provider of revenue cycle management services and healthcare technology solutions, is proud to announce the launch of MediFusion, a complete electronic health record (EHR) solution. MediFusion has received certification from the Office of the National Coordinator for Health Information Technology (ONC HIT) and Gaming Laboratories International, LLC dba SLI Compliance (SLI) before its launch.

MediFusion is a comprehensive EHR solution that streamlines the healthcare workflow by providing healthcare professionals with a single, centralized platform for managing patient records. It also offers a patient portal that enables patients to access their health information and communicate with their healthcare providers.

The ONC HIT certification confirms that MediFusion meets the federal government's standards for EHR technology, including patient data security and privacy, and the ability to share patient information electronically. The SLI certification ensures that MediFusion complies with the industry's standards for data security, data integrity, and patient privacy.

"We are thrilled to launch MediFusion and to receive these certifications," said CEO of Bellmedex, Mr. Qazafi Qureshi. "Our team has worked hard to develop a solution that not only simplifies the healthcare workflow but also meets the highest standards for patient data security and privacy. We are confident that Medifusion will be a valuable asset to healthcare providers and patients alike."

About Bellmedex

Bellmedex is a leading provider of healthcare solutions that improve the delivery of care and the patient experience. All solutions are designed to streamline the healthcare workflow, increase efficiency, and reduce costs.

For more information about MediFusion, please visit https://www.medifusion.com. 

Contact Information:
Andy Smith
Manager Marketing
[email protected]
4252761814‬


Original Source: Bellmedex is Revolutionizing Healthcare With MediFusion: The Complete EHR Solution Certified by ONC and SLI